FIELD: medicine.
SUBSTANCE: invention relates to a composition for treating breast cancer, wherein the composition contains tamoxifen and at least its metabolite endoxifene. This composition contains 15–25 mg of tamoxifen and 0.25–5.0 mg of endoxifen, while the dosage of tamoxifen and endoxifen is chosen based on the expression of CYP2D6 in patients undergoing treatment.
EFFECT: implementation of the invention allows to ensure a rapid achievement of the effect level of endoxifen and tamoxifen in plasma in patients with IM and PM.
3 cl, 18 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DETERMINING HUMAN GENOTYPE BY POLYMORPHISM IN THE CYTOCHROME GENE P450 CYP2D6*9 (2615-2617DELAAG) RS5030656 | 2016 |
|
RU2651773C2 |
| METHOD FOR DETERMINING HUMAN GENOTYPE BY POLYMORPHISM IN THE CYTOCHROME GENE P450 CYP2D6∗3 (2549DELA), RS35742686 | 2016 |
|
RU2651770C2 |
| METHOD FOR DETERMINING THE HUMAN GENOTYPE BY POLYMORPHISM IN THE CYTOCHROME P450 GENE CYP2D6*4 (1846G>A), RS3892097 | 2016 |
|
RU2651774C2 |
| METHOD FOR DETERMINING THE HUMAN GENOTYPE BY POLYMORPHISM IN THE CYTOCHROME P450 CYP2D6*6 (1707DELT) RS5030655 GENE | 2016 |
|
RU2653492C2 |
| METHOD FOR PREDICTION OF ANTI-OESTROGEN TAMOXIFEN THERAPY EFFECTIVENESS IN PATIENTS WITH LUMINAL BREAST CANCER | 2014 |
|
RU2558857C1 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING PROLIFERATIVE MAMMARY GLAND DISEASES | 2005 |
|
RU2318508C2 |
| METHOD FOR PREDICTION OF PREDISPOSITION TO COURSE OF POSTTRAUMATIC OSTEOARTHROSIS OF KNEE JOINT | 2014 |
|
RU2600860C2 |
| CHEMICALLY STABLE COMPOSITIONS OF 4-HYDROXY-TAMOXIFEN | 2005 |
|
RU2389483C2 |
| METHOD OF DETERMINING PERSON'S PREDISPOSAITION TO DEVELOPMENT OF AGGRESSIVE NON-HODGKIN'S LYMPHOMAS | 2008 |
|
RU2373862C1 |
| APPLICATION OF FULVESTRANT AT TREATING RESISTANT CANCER OF MAMMARY GLAND | 2001 |
|
RU2265438C2 |
